| Ytd | -60.65% | |
| 1y | -82.38% |
| Open | 1.14 | Prev Close | 1.14 | Low | 1.09 | High | 1.17 | Mkt Cap | 152.56M |
| Vol | 140.26K | Avg Vol | 1.25M | EPS | -3.56 | P/E | N/A | Forward P/E | -0.64 |
| Beta | 1.13 | Short Ratio | 0.54 | Inst. Own | 6.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 2.09 | 200-d Avg | 2.23 | 1yr Est | 8.50 |
INDP News
Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday&
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.02) per share which beat the an
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" o
STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential leg
U.S. stocks higher with Nasdaq up 2%. Ouster shares rise 15.8%, PAVS gains 92.1%. Other big gains in
U.S. stock futures rise, Nasdaq up 1%. Graham Corp shares down 8.7%. Other stocks declining in pre-m
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in
Solidion Technology, Inc. (NASDAQ: STI) rose 50.55% in pre-market trading on Friday after announcing
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.23) per share which beat the an
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or
Aldeyra Therapeutics (NASDAQ: ALDX - Get Free Report) and Indaptus Therapeutics (NASDAQ: INDP - Get
Indaptus Therapeutics (NASDAQ: INDP - Get Free Report) is expected to be issuing its results before
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” o
PATH: 8% | UiPath To Replace Synovus Financial In The S&P Midcap 400 Effective Prior To The Open
Indaptus Therapeutics surged 64.65% in after-hours trading following a major insider investment and
INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001857044/000149315225029107/form8-k.htm
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” o
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(2.98) per share which beat the an
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” o
Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Indaptus Therapeutics (NASDAQ: INDP - Get Fre
Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market ses
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday&#